Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

Clinicaltrials.gov Identifier:

nct06415175

Trial details

Trial date:

November 14, 2024 - September 30, 2026

Phase: N/A

Birth sex

Age range

6 Months to 11 Years

Accepts healthy volunteers

Condition(s) being studied:

Atopic Dermatitis

What is the type of trial?

Observational

What is the trial testing?

Dupilumab

How many people are being enrolled?

150

Inclusion Criteria:

* Male or female aged 6 months to 11 years old at baseline.

* Patients with severe Atopic dermatitis (AD) according to the investigator's assessment.

* Patients initiating dupilumab (in those patients initiated retrospectively 2 months before the start of the study, the baseline information must be correctly filled out in the medical records).

* Signed informed consent by the parent/legally acceptable representative and assent by the patient appropriate to the patient's age.

Exclusion Criteria:

* Patients who are participating in an interventional clinical trial that modifies patient care.

Trial summary

This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease characteristics, prior treatments for and treatment prescription modalities. As well as to document the real-world effectiveness and safety of dupilumab during the two years of follow up. No diagnostic or therapeutic intervention outside of routine clinical practice will be applied.

Trial locations

0 location(s)